Cytokinesis-block micronucleus assay of celecoxib and celecoxib derivatives.
Celecoxib
Chemoprevention
DNA damage
Micronucleus test
Journal
Toxicology reports
ISSN: 2214-7500
Titre abrégé: Toxicol Rep
Pays: Ireland
ID NLM: 101630272
Informations de publication
Date de publication:
2020
2020
Historique:
received:
13
07
2020
revised:
01
11
2020
accepted:
05
11
2020
entrez:
11
12
2020
pubmed:
12
12
2020
medline:
12
12
2020
Statut:
epublish
Résumé
Celecoxib is used widely for the acute treatment of pain and for pain relief in various diseases. Furthermore, it shows potential in chemoprevention, although chronic treatment with celecoxib could lead to adverse effects like cardiovascular events. New derivatives of celecoxib were synthesised that may be suitable as chemopreventive agent without inducing adverse effects. Critical endpoint for a safe use of pharmaceuticals is genotoxicity after application. A standard test for the assessment of genotoxicity is the cytokinesis-block micronucleus assay, that evaluates the number micronuclei after treatment of cells with a test compound as biomarker for DNA damage. Various promising derivatives of celecoxib have been assessed with the cytokinesis-block micronucleus assay in HeLa-H2B-GFP cells. It could be demonstrated, that neither celecoxib nor its derivatives were genotoxic in this assay and therefore celecoxib derivatives could be developed further for a safe use as chemopreventive agent.
Identifiants
pubmed: 33304828
doi: 10.1016/j.toxrep.2020.11.004
pii: S2214-7500(20)30435-2
pmc: PMC7708851
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1588-1591Informations de copyright
© 2020 The Author(s).
Déclaration de conflit d'intérêts
The authors report no declarations of interest.
Références
F1000Res. 2015 Sep 28;4(F1000 Faculty Rev):916
pubmed: 27006756
Cancer Manag Res. 2019 Jan 09;11:561-571
pubmed: 30666154
Chem Biodivers. 2019 Jun;16(6):e1900108
pubmed: 30977306
Bioorg Med Chem. 2017 Sep 1;25(17):4887-4893
pubmed: 28757100
Ann Pharmacother. 2001 Jul-Aug;35(7-8):829-34
pubmed: 11485128
Curr Cancer Drug Targets. 2019;19(1):5-16
pubmed: 29714143
Arch Toxicol. 2011 Aug;85(8):873-99
pubmed: 21537955
Curr Mol Pharmacol. 2018;11(3):173-183
pubmed: 29468988
Circulation. 2005 Apr 5;111(13):1713-6
pubmed: 15781731
Cochrane Database Syst Rev. 2017 Jun 09;6:CD012095
pubmed: 28597983
Nature. 2012 Jan 18;482(7383):53-8
pubmed: 22258507
Nat Protoc. 2007;2(5):1084-104
pubmed: 17546000
Toxicol Lett. 2019 Nov;316:154-170
pubmed: 31521832
Expert Opin Investig Drugs. 2008 Feb;17(2):197-208
pubmed: 18230053
Prostaglandins Other Lipid Mediat. 2020 Apr;147:106379
pubmed: 31726219
Oncol Lett. 2019 Mar;17(3):2703-2712
pubmed: 30854044
Mutat Res. 2018 Jul - Sep;777:29-51
pubmed: 30115429
Toxicol Rep. 2020 Aug 30;7:1090-1094
pubmed: 32953461
Curr Biol. 1998 Mar 26;8(7):377-85
pubmed: 9545195
Nat Protoc. 2009;4(6):825-37
pubmed: 19444240
Oncotarget. 2018 Sep 14;9(72):33656-33681
pubmed: 30263093
Cochrane Database Syst Rev. 2017 May 22;5:CD009865
pubmed: 28530031
Mutagenesis. 2003 May;18(3):221-33
pubmed: 12714687
Res Pharm Sci. 2017 Feb;12(1):82-87
pubmed: 28255318
Carcinogenesis. 2007 Mar;28(3):625-31
pubmed: 16973674
Proc Natl Acad Sci U S A. 1999 Jan 5;96(1):272-7
pubmed: 9874808
Curr Drug Targets. 2003 Jan;4(1):45-54
pubmed: 12528989